Version 2 2016-10-28, 14:22Version 2 2016-10-28, 14:22
Version 1 2016-10-25, 17:34Version 1 2016-10-25, 17:34
journal contribution
posted on 2016-10-17, 00:00authored byKeun Ah Ryu, Katarzyna Slowinska, Troy Moore, Aaron Esser-Kahn
We report immune
response modulation with linked Toll-like receptor
(TLR) agonists. Conjugating two agonists of synergistic TLRs induce
an increase in immune activity compared to equal molarity of soluble
agonists. Additionally, varying the distance between the agonists
by changing the linker length alters the level of macrophage NF-κB
activity as well as primary bone marrow derived dendritic cell IL-6
production. This modulation is effected by the size of the agonists
and the pairing of the stimulated TLRs. The sensitivity of linker-length-dependent
immune activity of conjugated agonists provides the potential for
developing application specific therapeutics.